SALIX PHARMACEUTICALS LTD 4
4 · SALIX PHARMACEUTICALS LTD · Filed Apr 3, 2015
Insider Transaction Report
Form 4
CHAPPELL JOHN F
Director
Transactions
- Disposition to Issuer
Common Stock
2015-04-01$173.00/sh−294,120$50,882,760→ 0 total - Disposition to Issuer
Common Stock
2015-04-01$173.00/sh−28,644$4,955,412→ 0 total(indirect: By Spouse)
Footnotes (1)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated as of February 20, 2015 (as amended, the "Merger Agreement"), by and among the Issuer, Valeant Pharmaceuticals International ("VPI"), a Delaware corporation and a wholly owned subsidiary of Valeant, Sun Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and a wholly owned subsidiary of VPI, and Valeant Pharmaceuticals International, Inc. ("Valeant"), a British Columbia corporation, on April 1, 2015, each share of the Issuer's common stock and each share of the Issuer's restricted stock issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement), other than shares then owned by Valeant, VPI, Merger Sub or by any of their wholly owned subsidiaries, and shares held by the Issuer or by any of its wholly owned subsidiaries, were converted into the right to receive $173.00 per share in cash, subject to any applicable withholding taxes.